Benzinga | Jan 22, 2021 08:05AM EST

Equillium Reports Acceptance Of Late-Breaking Abstract For Oral Presentation Of Interim Data From EQUATE Study In Acute GVHD At 2021 TCT Meetings Feb. 8-12

Equillium, Inc. (NASDAQ:EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021.

Title: Preliminary Safety and Efficacy of Itolizumab, A Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Severe Acute Graft-Versus-Host Disease: Interim Results from Equate Study

First Author: John Koreth, MBBS, Ph.D. director of translational research, stem cell transplantation, Dana-Farber Cancer Institute

Date and Time: Friday, February 12 at 2:00 p.m. CST / 3:00 p.m. EST

Abstract ID Number: LBA4